{"Groups": [{"Channels": ["pCDK1/2/3/5", "pHH3", "DNA", "pan-cytokeratin"], "Colors": ["ff0000", "00ff00", "0000ff", "ffffff"], "Name": "Cell Cycle", "Path": "Cell-Cycle_5__pCDK1"}, {"Channels": ["CD8a", "CD4", "DNA", "pan-cytokeratin"], "Colors": ["ff0000", "00ff00", "0000ff", "ffffff"], "Name": "T Cells", "Path": "T-Cells_19__CD8a--17__CD4--0__DNA--10__panCK"}, {"Channels": ["CD68", "CD163", "CD14", "DNA", "pan-cytokeratin"], "Colors": ["ff0000", "00ff00", "ff00ff", "0000ff", "ffffff"], "Name": "Macrophages", "Path": "Macrophages_22__CD68--21__CD163--23__CD14--0__DNA--10__panCK"}], "Header": "This is a CyCIF image of a biopsy from a patient with triple-negative breast cancer (TNBC) liver metastasis. The biopsy was obtained after combination therapy with Cisplatin and the Wee1 inhibitor Adavosertib at cycle 2. According to the RECIST 1.1 response evaluation criteria, this patient was classified as having a partial response (PR) to the combination therapy.\n", "Images": [{"Description": "Clinical Benefit - Cis Wee1i Biopsy", "Height": 4212, "MaxLevel": 4, "Name": "i0", "Path": "https://s3.amazonaws.com/www.cycif.org/keenan-2020/Wee1", "Width": 16200}], "Layout": {"Grid": [["i0"]]}, "Rotation": 0, "Stories": [{"Description": "", "Name": "", "Waypoints": [{"Arrows": [], "Description": "We detected changes in cell cycle markers on the biopsy obtained after the combination therapy of Cisplatin and Wee1 inhibitor. Within the pan-cytokeratin+ tumor cell population, CyCIF revealed that pCDK1/2/3/5 expression decreased on average 56%, from monotherapy to combination therapy biopsies, indicating target engagement of the Wee1 inhibitor. Similarly, the number of pHH3+ tumor cells increased by an average of 28-fold from monotherapy to combination therapy biopsies, suggesting increased entry into mitosis after Wee1 inhibitor therapy.", "Group": "Cell Cycle", "Name": "Cell Cycle", "Overlays": [{"height": 0.10085309851268642, "width": 0.08953908143426004, "x": 1.4997692731817849, "y": 0.3971996699578588}], "Pan": [1.6023507234736716, 0.40304400233822046], "Zoom": 2.7121214884672566}, {"Arrows": [], "Description": "Patients with more favorable responses had increased CD3+CD4+ and CD3+CD8a+ T cell infiltration following Wee1 inhibitor therapy. There were larger increases in CD3+CD4+ and CD3+CD8a+ T cell populations in patients who had either a partial response (PR) or stable disease (SD) versus those with progressive disease (PD).\n", "Group": "T Cells", "Name": "T Cells (I)", "Overlays": [{"height": 0.07081724884201085, "width": 0.07209700828083054, "x": 0.9184333372240276, "y": 0.341956834361273}], "Pan": [0.9572415681537971, 0.3520201552567881], "Zoom": 3.7405025139276096}, {"Arrows": [], "Description": "There are mutliple T cell dense regions in this biopsy.\n", "Group": "T Cells", "Name": "T Cells (II)", "Overlays": [], "Pan": [1.2005834159791435, 0.3310691717682681], "Zoom": 2.7143342234968046}, {"Arrows": [], "Description": "We observed a small increase in the CD68+ macrophage population after Wee1 inhibition therpy in this partial responder.\n", "Group": "Macrophages", "Name": "Macrophages", "Overlays": [{"height": 0.12712715990312895, "width": 0.11941124088202759, "x": 1.208592073602707, "y": 0.26683604359683055}], "Pan": [1.254304134724845, 0.3199711104177466], "Zoom": 2.428840983205784}]}]}